Commerzbank Aktiengesellschaft FI Boosts Stock Holdings in Zoetis Inc. $ZTS

Commerzbank Aktiengesellschaft FI increased its stake in Zoetis Inc. (NYSE:ZTS) by 51.8% during the 2nd quarter, Holdings Channel reports. The fund owned 23,854 shares of the company’s stock after purchasing an additional 8,145 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Zoetis were worth $1,714,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. J. Stern & Co. LLP increased its holdings in Zoetis by 12,431.2% during the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after purchasing an additional 23,877,416 shares during the period. Norges Bank purchased a new position in shares of Zoetis in the 4th quarter valued at about $734,425,000. Vanguard Group Inc. boosted its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after buying an additional 5,474,210 shares during the period. Ruane Cunniff & Goldfarb L.P. acquired a new position in shares of Zoetis during the first quarter worth about $286,660,000. Finally, Van ECK Associates Corp increased its stake in shares of Zoetis by 269.0% during the fourth quarter. Van ECK Associates Corp now owns 2,387,059 shares of the company’s stock worth $300,340,000 after buying an additional 1,740,113 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $72.71 on Tuesday. The company’s fifty day moving average price is $76.17 and its 200 day moving average price is $98.47. Zoetis Inc. has a 12 month low of $71.00 and a 12 month high of $160.48. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market capitalization of $30.05 billion, a P/E ratio of 11.98, a P/E/G ratio of 1.28 and a beta of 0.73.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. Zoetis’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Analyst Ratings Changes

Several research analysts have commented on the stock. UBS Group lowered their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Friday, August 7th. Piper Sandler decreased their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research report on Monday, August 10th. TD Cowen decreased their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. William Blair reissued a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Finally, Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.